Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis

BACKGROUND: The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuria, and was terminated prematurely due to overwhelming effica...

Descripción completa

Detalles Bibliográficos
Autores principales: McEwan, Phil, Boyce, Rebecca, Sanchez, Juan Jose Garcia, Sjöström, C David, Stefansson, Bergur, Nolan, Stephen, Correa-Rotter, Ricardo, Rossing, Peter, Chertow, Glenn M, McMurray, John J V, Wheeler, David C, Heerspink, Hiddo J L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157747/
https://www.ncbi.nlm.nih.gov/pubmed/36301617
http://dx.doi.org/10.1093/ndt/gfac280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157747/
https://www.ncbi.nlm.nih.gov/pubmed/36301617
http://dx.doi.org/10.1093/ndt/gfac280

Ejemplares similares